Furthermore, the combination of ML‐210 and ED‐71 also synergistically inhibited tumour growth (synergy index > 10) (Figure 9C–F), as the simultaneous inhibition of GPX4 and GPX1 disrupts their compensatory responses, offering a promising strategy for cancer therapy. Here, GPX1 is linked to cancer.